Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation.

Journal for immunotherapy of cancer - 1 Jul 2022

Wen Lei, Chen Zhigang, Ji Xiaomeng, Fong William Pat, Shao Qiong, Ren Chao, Cai Yanyu, Li Binkui, Yuan Yunfei, Wang Deshen, Li Yuhong

Abstract excerpt

Patients with polymerase epsilon (POLE) exonuclease domain mutation (EDM) exhibits distinct clinical characteristics and extremely high tumor mutation burden (TMB). There is a paucity of data on the therapeutic efficacy of immune checkpoint inhibitors (ICIs) for the treatment of colorectal cancer liver metastases (CRLM) patients with POLE EDM. Clinical characteristics, radiological and pathological response, as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Liver Neoplasms

Share to Mutation

Share to Poly-ADP-Ribose Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35793867
DOI: 10.1136/jitc-2022-004487
PMCID: PMC9260839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation.PMID 35793867Read ↗

Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.Semantic proximity Read ↗

Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world dataSemantic proximity Read ↗

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to favorable survival of tumors with POLE mutations outside the exonuclease domainSemantic proximity Read ↗

Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.Semantic proximity Read ↗

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Semantic proximity Read ↗

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.Semantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.Semantic proximity Read ↗

Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumorsSemantic proximity Read ↗

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapySemantic proximity Read ↗

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.Semantic proximity Read ↗

Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.